AbbVie will buy Aliada Therapeutics for $1.4 billion in cash, it said on Monday, gaining access to the privately held therapy developer's Alzheimer's disease candidate as the U.S. drugmaker increases ...
According to Research by , The Antipsychotic Drugs Market is Expected to Grow at a CAGR of 6.53% Through 2032, Supported by Increasing Prevalence of Psychotic Disorders, Advancements in Medication ...
lifted its stake in Alkermes by 87.1% in the second quarter. American Century Companies Inc ... It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid ...
Beacon Hill Roll Call records local senators’ votes on the only roll call from the week of Oct. 21-25. There were no roll calls in the House last week. CLEAN ENERGY AND ...
HC Wainwright reissued their neutral rating on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a $37.00 ...